Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of TAK-164 in GCC-expressing advanced gastrointestinal cancers
NL-OMON48866Phase 1Active, not recruiting
- Sponsor
- Takeda
- Start
- Dec 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAK-164 in gastrointestinal cancer, colorectal cancer (CRC), gastric cancer (GC) and 3 more (3 arms), sponsored by Takeda. Primary endpoints: Number of patients with a dose-limiting toxicity, Percentage of patients with adverse events and 8 more. Started Dec 2019; status: active, not recruiting.
02
Drugs
TAK-164
03
Conditions
gastrointestinal cancercolorectal cancer (CRC)gastric cancer (GC)esophageal cancersmall bowel cancer
Beyond the preview
Go deeper on NL-OMON48866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48866.